Title:
PHARMACEUTICAL COMPOSITION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/121917
Kind Code:
A1
Abstract:
Disclosed are a pharmaceutical composition and the use thereof, in particular a recombinant adenovirus vector vaccine composition, a vaccine preparation (in particular a liquid preparation) and the use thereof in preventing and/or treating diseases. The above-mentioned composition can be used to prepare a vaccine (in particular a recombinant vector vaccine, such as a recombinant adenovirus vector vaccine) preparation (in particular a liquid preparation). The vaccine preparation can effectively prevent antigen aggregation, has good stability, can be stored stably at 2-8°C for at least 2 years, at 25°C for at least 3 months, and at 37°C for at least 2 weeks, and can still maintain a relatively good antigenic activity after repeated freezing and thawing. In addition, an abnormal toxicity test performed thereon is qualified and same is safe to use.
Inventors:
SI WEIXUE (CN)
LI JUNQIANG (CN)
DENG JIE (CN)
XIAO MENG (CN)
MA CHAO (CN)
XU YUNLI (CN)
DONG XIAOMAN (CN)
CHEN LIESHENG (CN)
ZHU TAO (CN)
CHAO SHOUBAI (CN)
LI JUNQIANG (CN)
DENG JIE (CN)
XIAO MENG (CN)
MA CHAO (CN)
XU YUNLI (CN)
DONG XIAOMAN (CN)
CHEN LIESHENG (CN)
ZHU TAO (CN)
CHAO SHOUBAI (CN)
Application Number:
PCT/CN2021/136293
Publication Date:
June 16, 2022
Filing Date:
December 08, 2021
Export Citation:
Assignee:
CANSINO BIOLOGICS INC (CN)
International Classes:
A61K47/22; A61K9/08; A61K39/12; A61K47/02; A61K47/26; A61K47/34; A61P31/14
Foreign References:
| CN113750227A | 2021-12-07 | |||
| CN105267960A | 2016-01-27 | |||
| CN109415739A | 2019-03-01 | |||
| CN111218459A | 2020-06-02 | |||
| CN110974950A | 2020-04-10 | |||
| CN106492213A | 2017-03-15 |
Attorney, Agent or Firm:
BEIJING LINKTEC IP LAW FIRM (SPECIAL GENERAL PARTNERSHIP) (CN)
Download PDF: